NATANEA CATALYST - The morning phase of the NATANEA Protocol.

Sirtuins are a family of seven enzymes (SIRT1 through SIRT7) that act as cellular sensors of metabolic health. They influence mitochondrial biogenesis, DNA repair, inflammatory regulation, and oxidative-stress response — all four of which directly shape the biological environment in which oocytes mature.

The most studied of these enzymes, SIRT1, is activated by NAD+ availability and by a small group of dietary polyphenols. Trans-resveratrol is the most-cited of those polyphenols in the peer-reviewed reproductive literature.

SIRT1 activation has been associated, in published in vitro and clinical studies, with: improved mitochondrial function in granulosa cells, reduced reactive oxygen species (ROS) in follicular fluid, increased PGC-1α and TFAM expression (markers of mitochondrial biogenesis), and modulation of the inflammatory response inside the ovarian microenvironment.

This is not a claim that CATALYST does any of those things in your body. It is a description of the biological pathway the formulation was designed to support — a distinction we take seriously.

The single biggest problem with oral trans-resveratrol is bioavailability. Multiple human pharmacokinetic studies have shown that less than 1% of an unformulated dose reaches systemic circulation in its active form. The rest is rapidly metabolized in the liver into glucuronide and sulfate conjugates — molecules with very different biological activity than the parent compound.

For a resveratrol supplement to have any plausible biological effect, it must address three barriers:

• Solubility. Resveratrol is highly lipophilic. Without a fat-soluble delivery vehicle, oral absorption is inconsistent and dose-dependent.
• First-pass metabolism. The liver converts most of the absorbed dose into conjugated forms within minutes. Co-administration with piperine (black pepper extract) has been shown in human studies to inhibit specific glucuronidation enzymes and meaningfully extend the half-life of the active compound.
• Cellular uptake. Once in circulation, trans-resveratrol must cross cell membranes to reach its intracellular targets. Formulation with phospholipid complexes or absorption enhancers can improve this final step.

CATALYST was formulated around all three barriers — not around marketing.

The 600 mg per-dose was selected based on the published clinical literature, not on marketing differentiation. Peer-reviewed reproductive studies using trans-resveratrol have tested per-administration doses between 150 mg and 800 mg, with the majority concentrated around 400-600 mg.

Below 150 mg, biological effects in human studies are inconsistent. Above 1,000 mg in a single administration, gastrointestinal side effects (diarrhea, abdominal discomfort) begin to appear in a meaningful proportion of participants without clear additional biological benefit.

The 600 mg per-dose places CATALYST in the middle of the clinically-studied range. Taken twice daily across the morning — one capsule with breakfast, one mid-morning — the split-dose maintains plasma trans-resveratrol concentration across the SIRT1 circadian peak window, without exceeding single-administration thresholds.

SIRT1 activity is not constant across the 24-hour cycle. It follows a clear circadian rhythm in healthy adults, with peak enzymatic activity in the early waking hours — roughly between 6 AM and 12 PM — driven by morning cortisol release and the metabolic shift from overnight fasting to first meal intake.

Taking CATALYST as two doses across the morning, each 20-30 min before a meal containing some dietary fat, serves three simultaneous purposes:

• Aligns supplementation with the SIRT1 circadian peak, when the cellular machinery is most responsive to substrate availability.
• Maintains plasma trans-resveratrol concentration across the full 6 AM - 12 PM peak window, rather than producing a single short-lived spike — a split-dose pharmacokinetic strategy used in clinical research on lipophilic polyphenols.
• Enables liposoluble absorption, which is essential for a lipophilic compound like trans-resveratrol to reach therapeutic plasma levels.

Taking it on an empty stomach, in a single dose, or in the evening, defeats all three purposes. This is why CATALYST is structured as a split-dose morning protocol — paired with the evening dose of NATANEA — not as a "take whenever" supplement.